MESO stock news · Mesoblast

Stories about Mesoblast (MESO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MESO

Follow Mesoblast (MESO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 29, 2026, 7:04 PM ET · Market
Mesoblast shares its financial and business updates for the first quarter of fiscal 2026.
Good for MESO
Mesoblast reported 44% higher quarterly sales, an 86% improvement in cash use, and growing RYONCIL demand. These gains make the update favorable, though trial results and a filing remain pending.
Aug 17, 2026, 1:57 PM ET · Market
Regenerative therapy for back pain aims for a $10 billion market, according to Mesoblast.
Good for MESO
Mesoblast's stock is trading higher following the completion of patient dosing in its Phase 3 clinical trial for rexlemestrocel-L, a treatment for chronic low back pain. This advancement not only enhances the company's prospects in a lucrative market but also underscores the growing interest and demand for innovative therapies in pain management.